Marketing-authorisation holder · United States
Genzyme Corporation
21 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
21 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
21 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CAMPATH10mg/ml | 30mg/ml · Vial | Alemtuzumab | United States | Marketed | 2001 |
| CAPRELSA100mg | 300mg · Tablet | Vandetanib | United States | Marketed | 2011 |
| CERDELGA84mg base · Capsule | Eliglustat | United States | Marketed | 2014 |
| CEREZYME200 units/vial | 400 units/vial · Injectable | Imiglucerase | United States | Marketed | 1994 |
| CLOLAR20mg/20ml (1mg/ml) · Solution | Clofarabine | United States | Not marketed | 2004 |
| FABRAZYME35mg/vial | 5mg/vial · Vial | Agalsidase beta | United States | Marketed | 2003 |
| FLUDARA50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Fludarabine | United States | Not marketed | 1991 |
| LEMTRADA12mg/1.2ml (10mg/ml) · Injectable | Alemtuzumab | United States | Marketed | 2001 |
| LUMIZYME5mg/ml · Powder | Alglucosidase alfa | United States | Marketed | 2010 |
| MOZOBIL24mg/1.2ml (20mg/ml) · Solution | Plerixafor | United States | Marketed | 2008 |
| MYOZYME20mg/kg · Injectable | Alglucosidase alfa | United States | Marketed | 2006 |
| NEXVIAZYME100mg · Injectable | Avalglucosidase alfa-ngpt | United States | Marketed | 2021 |
| QFITLIA20mg base/0.2ml (eq 20mg base/0.2ml) | 50mg base/0.5ml (eq 50mg base/0.5ml) · Solution | Fitusiran | United States | Marketed | 2025 |
| RENAGEL400mg | 800mg · Tablet | Sevelamer | United States | Marketed | 2000 |
| RENAGEL403mg · Capsule | Sevelamer | United States | Not marketed | 1998 |
| RENVELA2.4gm/packet | 800mg/packet · For suspension | Sevelamer | United States | Marketed | 2009 |
| Thymoglobulin25mg · For Injection | Antithymocyte immunoglobulin (rabbit) | United States | Marketed | 1999 |
| THYROGEN1.1mg/vial · Injectable | Thyrotropin alfa | United States | Marketed | 1998 |
| WAYRILZ400mg · Tablet | Rilzabrutinib | United States | Marketed | 2025 |
| XENPOZYME20mg · Injectable | Olipudase alfa-rpcp | United States | Marketed | 2022 |
| Xenpozyme4MG · For Injection | Olipudase alfa | United States | Marketed | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 21 | 21 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.